External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues and deployment of resources and training where necessary.
ECDC has worked with EU/EEA countries to develop a methodology for regular national reporting of existing national surveillance data on COVID-19 in LTCFs, aiming for maximum feasibility. This is to enable ECDC to communicate timely information on epidemiological trends of COVID-19 in LTCFs, in support of national and EU/EEA-level preparedness and response activities.
Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues, and deployment of resources and training where necessary.
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
A pilot project was carried out to investigate the feasibility of HIVDR surveillance in EU/EEA countries and to make recommendations for the design and implementation of a potential future HIVDR surveillance system at the European level.